Telescope Innovations Conditionally Approved for up to $3.36 M in Government Funding to Advance Lithium Processing Technology

Federal support accelerates Telescope's continued development, demonstration and scale-up of lithium recycling and solid-state battery materials technologies

Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U)  ("Telescope Innovations", "Telescope", or the "Company") is a leader in providing intelligent automation platforms and services that accelerate chemical process development. The Company is pleased to announce that two Government of Canada funding streams totalling up to CAD $3.36 M have been formally or conditionally awarded to Telescope to support the advancement of its lithium processing technologies. Canada's Minister of Energy and Natural Resources, the Honourable Tim Hodgson, announced this support on the margins of the recent G7 Energy and Environment Ministers' meeting in Toronto.

The Company is receiving advisory services and up to $319,200 in funding support from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") for a research and development program to demonstrate Telescope's lithium carbonate crystallization technology, ReCRFT™, for battery recycling applications. This effort is part of a consortium project with the NRC IRAP United Kingdom Research and Innovation (UKRI) critical minerals initiative, aimed at building critical mineral recycling knowledge and expertise with international partners. Through Natural Resources Canada's ("NRCan") Critical Minerals Research, Development and Demonstration (CMRDD) program, a further $3.04 M is also conditionally approved to scale-up and pilot Telescope's low-temperature lithium sulphide process, DualPure™. This process could build a viable, local, high purity supply chain that produces a key ingredient of next-generation batteries.

"We deeply appreciate the confidence and support from the NRC and NRCan," said Henry Dubina, CEO of Telescope. "These investments, combined with our AI and automation-driven development model, position us to rapidly translate Canadian technology into real-world processes that support the clean-energy transition."

"Research and development are at the heart of building resilient and sustainable critical mineral supply chains. Through the G7 Critical Minerals Action Plan, we are collaborating with trusted international partners to advance innovative projects — like the work led by Telescope Innovations — that reduce environmental impacts, maximize production and strengthen Canada and our allies' competitive edge," said Minister Hodgson.

"Research and development are the driving forces behind Canada's leadership in critical minerals. Through strategic collaboration with international partners and innovative companies like Telescope Innovations, we are accelerating breakthroughs across the supply chain — from exploration to processing — ensuring our solutions are sustainable, competitive and globally impactful," added Claude Guay, Parliamentary Secretary to Canada's Minister of Energy and Natural Resources.

BOLSTERING RESILIENCE IN THE BATTERY SUPPLY CHAIN

By demonstrating lithium carbonate recovery from waste, and scaling efficient lithium sulphide synthesis, Telescope is helping on-shore advanced manufacturing of battery materials. The battery recycling technology based on ReCRFT™ has advanced from research discovery to demonstration in just one year, aligning with the rapidly growing global market demand for a circular lithium supply. Meanwhile, DualPure™ is also advancing towards commercialization just as global battery manufacturers accelerate solid-state battery programs, driving unprecedented demand for high-purity lithium sulphide.

"These investments will allow us to turn innovation into impact for this emerging industry," said Dubina. "We're building technologies that make battery materials cleaner, more secure, and ready for the next generation of energy systems."

PROCESS DEVELOPMENT POWERED BY INTELLIGENT AUTOMATION

Both lithium refinement programs run through Telescope's intelligent automation laboratory infrastructure, combining automated experimentation with advanced analytical technologies and "Self-Driving Labs". The Company's automation-first R&D model enables rapid iteration and generates reproducible, data-rich process insights needed for scale-up and deployment. As a result, new chemical processes can be brought from proof-of-concept to demonstration and scale-up much faster and at significantly lower cost than traditional development timelines.

About Telescope Innovations

Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.

On behalf of the Board,

Telescope Innovations Corp.

Henry Dubina, Chief Executive Officer
E: henry.dubina@telescopeinn.com

Forward-Looking Information

Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, and uncertainties that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.

Forward-looking statements in this document include the Company's expectations for the receipt and use of government funding; the development, scale-up, demonstration, and potential commercialization of the Company's ReCRFT™ and DualPure™ technologies; anticipated benefits of these technologies for the lithium supply chain and battery materials markets; the Company's ability to accelerate process development through automation, and all other statements that are not statements of historical fact.

The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273055

News Provided by Newsfile via QuoteMedia

TELI:CC
The Conversation (0)
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News